[Prevention of Recurrence by Salazosulfapyridine (azulfidine) Therapy in Crohn's Disease. A Double Blind Study]
Overview
Affiliations
Iheozor-Ejiofor Z, Gordon M, Clegg A, Freeman S, Gjuladin-Hellon T, MacDonald J Cochrane Database Syst Rev. 2019; 9:CD013210.
PMID: 31513295 PMC: 6741529. DOI: 10.1002/14651858.CD013210.pub2.
Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng A Cochrane Database Syst Rev. 2019; 6:CD008414.
PMID: 31220875 PMC: 6586553. DOI: 10.1002/14651858.CD008414.pub3.
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.
Akobeng A, Zhang D, Gordon M, MacDonald J Cochrane Database Syst Rev. 2016; 9:CD003715.
PMID: 27681657 PMC: 6457838. DOI: 10.1002/14651858.CD003715.pub3.
Aminosalicylates for induction of remission or response in Crohn's disease.
Lim W, Wang Y, MacDonald J, Hanauer S Cochrane Database Syst Rev. 2016; 7:CD008870.
PMID: 27372735 PMC: 6457996. DOI: 10.1002/14651858.CD008870.pub2.
Ewe K, Malchow H, Herfarth C Langenbecks Arch Chir. 1984; 364:427-30.
PMID: 6150408 DOI: 10.1007/BF01823251.